Qiagen N.V. (QGEN)
| Previous Close | 42.98 |
| Open | 43.10 |
| Bid | 42.69 x 800 |
| Ask | 42.69 x 800 |
| Day's Range | 42.59 - 43.12 |
| 52 Week Range | 34.74 - 47.70 |
| Volume | |
| Avg. Volume | 1,023,241 |
| Market Cap | 9.472B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 28.09 |
| EPS (TTM) | 1.52 |
| Earnings Date | Apr 30, 2024 |
| Forward Dividend & Yield | 1.28 (2.94%) |
| Ex-Dividend Date | Jan 30, 2024 |
| 1y Target Est | 50.17 |
ZacksInternational Markets and Qiagen (QGEN): A Deep Dive for Investors
Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
GlobeNewswireQIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence // Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inher
Simply Wall St.Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a good week for Qiagen N.V. ( NYSE:QGEN ) shareholders, because the company has just released its latest...
